Glycotex Inc. Obtains Active IND From US FDA for GLYC-101 Wound Healing Compound
ROCKVILLE, MD--(Marketwire - January 07, 2008) - Glycotex, Inc. announced today that it had obtained an active Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA) for the start of a phase IIa clinical trial of its lead product candidate GLYC-101, administered topically for the treatment of burn wounds.